A panel of IgG1 b12 variants with selectively diminished or enhanced affinity for Fcγ receptors to define the role of effector functions in protection against HIV.
about
Conformational Masking and Receptor-Dependent Unmasking of Highly Conserved Env Epitopes Recognized by Non-Neutralizing Antibodies That Mediate Potent ADCC against HIV-1A New Scientific Paradigm may be Needed to Finally Develop an HIV VaccineAAV-Delivered Antibody Mediates Significant Protective Effects against SIVmac239 Challenge in the Absence of Neutralizing ActivityHumoral and Innate Antiviral Immunity as Tools to Clear Persistent HIV InfectionWhich Antibody Functions are Important for an HIV Vaccine?HIV-1 Vpu antagonism of tetherin inhibits antibody-dependent cellular cytotoxic responses by natural killer cells.Epitope target structures of Fc-mediated effector function during HIV-1 acquisition.Nonneutralizing functional antibodies: a new "old" paradigm for HIV vaccinesEnhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo.Exploring the potential of monoclonal antibody therapeutics for HIV-1 eradication.Antibody-dependent cellular cytotoxicity against primary HIV-infected CD4+ T cells is directly associated with the magnitude of surface IgG binding.Opportunities to exploit non-neutralizing HIV-specific antibody activity.Epitope specificity of human immunodeficiency virus-1 antibody dependent cellular cytotoxicity [ADCC] responses.Divergent antibody subclass and specificity profiles but not protective HLA-B alleles are associated with variable antibody effector function among HIV-1 controllers.Multiplexed Fc array for evaluation of antigen-specific antibody effector profiles.Non-neutralizing antibodies in prevention of HIV infection.HIV-specific antibody-dependent cellular cytotoxicity: a novel vaccine modality.Mouse and human FcR effector functions.Diversity of Antiviral IgG Effector Activities Observed in HIV-Infected and Vaccinated Subjects.Use of broadly neutralizing antibodies for HIV-1 prevention.Envelope-specific antibodies and antibody-derived molecules for treating and curing HIV infectionLack of ADCC Breadth of Human Nonneutralizing Anti-HIV-1 Antibodies.Antibody Functional Assays as Measures of Fc Receptor-Mediated Immunity to HIV - New Technologies and their Impact on the HIV Vaccine Field.Protective effect of vaginal application of neutralizing and nonneutralizing inhibitory antibodies against vaginal SHIV challenge in macaques.Natural Killer (NK) Cell Education Differentially Influences HIV Antibody-Dependent NK Cell Activation and Antibody-Dependent Cellular Cytotoxicity.Functional polymorphisms in rhesus macaque FCGRT and β2-m.Enhanced phagocytic activity of HIV-specific antibodies correlates with natural production of immunoglobulins with skewed affinity for FcγR2a and FcγR2b.Chemically Programmed Antibodies AS HIV-1 Attachment Inhibitors.Conserved HIV Epitopes for an Effective HIV Vaccine.Enrichment of high affinity subclasses and glycoforms from serum-derived IgG using FcγRs as affinity ligands.Importance of Fc-mediated functions of anti-HIV-1 broadly neutralizing antibodies
P2860
Q26782237-13CFF031-C3DD-4ACC-AEEF-90898A2497B2Q26830360-3A7E538B-E336-4D40-A882-4F10C088EF34Q27318266-4A27A283-F541-479D-B90A-08DCBEA51D35Q33620546-2DB06660-E284-4A64-AF27-0A0BB92FE406Q33772637-A4637F9D-0D39-4F1B-B6D1-592588A2A376Q33887674-4BB1FEE6-35BE-4813-B588-CDEB5EA2B773Q33924272-1F61B57D-C64D-4B87-99AD-8FFEA5BA6BB2Q34057711-068F2C9A-88FB-4772-B19F-F4953090307BQ34593860-D05FD003-C459-4D99-875A-E5D670FA855BQ34869927-D0D26634-5C2D-41F4-B399-CA1E6C569588Q36172128-33A2C237-175A-4CA7-B914-17C091A29058Q37113941-DA526334-94AF-43EC-8564-EFEE132B2844Q37426168-1BCE6635-CB56-42EE-BB73-6B58511CA6C4Q37643973-E72598F4-A3C4-4BD1-BC2D-0786D809BC09Q37677278-F2F155A1-95A9-4D9D-B05B-B379998EFDD6Q38058120-DC43DC39-9052-4029-BC4F-F4456E8CD6F1Q38061191-F2D2BC30-9C48-4FEA-9217-797D9B12ED68Q38615349-CE8F5324-21DB-4BED-BF64-669303E30747Q38727815-6AF78E74-077C-46B1-9E39-9E0887E42967Q38764543-12337523-4F0F-4D70-88F0-AE949FF6C59CQ38977425-0148375D-9AAC-49A5-AB2C-83955B854348Q38998925-D2992D23-3B8E-44D7-8669-8E5A2DBE4A78Q39189458-73EDEEDB-B9C3-4449-A73C-2BED0925696EQ39265150-232F33F0-2FEA-44A3-A98F-912DC756E639Q40052007-E8968168-866E-4F80-A2BB-EF445F1EC122Q40091355-AFB7D753-C911-49D9-86E2-C402FEC62B21Q40529181-8DF71763-E7BC-4756-935A-99CB16FE5AC7Q41585863-4DD14897-A73B-4D79-B3BF-74E9FA7F38CFQ47093684-A38BFC7B-7397-4649-B932-1FC773ECCC3DQ47190029-9D908AC2-EC35-404D-AAB2-3832FAE26E13Q58724429-7D453E96-0E7E-4419-9835-7FDB478A8E54
P2860
A panel of IgG1 b12 variants with selectively diminished or enhanced affinity for Fcγ receptors to define the role of effector functions in protection against HIV.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
A panel of IgG1 b12 variants w ...... ons in protection against HIV.
@en
type
label
A panel of IgG1 b12 variants w ...... ons in protection against HIV.
@en
prefLabel
A panel of IgG1 b12 variants w ...... ons in protection against HIV.
@en
P2093
P2860
P356
P1433
P1476
A panel of IgG1 b12 variants w ...... ons in protection against HIV.
@en
P2093
Ann J Hessell
Brian Moldt
D Cameron Dunlop
David T Evans
Dennis R Burton
Jackson D Harvey
Michael D Alpert
Niccole Schultz
P2860
P304
10572-10581
P356
10.1128/JVI.05541-11
P407
P577
2011-08-17T00:00:00Z